Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules.
Lupin Limited has signed an exclusive license and supply agreement with DKSH to commercialize five of Alvotech’s proposed biosimilars in the Philippines.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.
